Exploring the gut microbiome in IBS patients
Official title: IBS Personalized Diet vs. Low FODMAP Diet Randomized Control Trial
Run by Weizmann Institute of Science · NCT05972317 · Data updated 2026-11-12
This study is testing how a low FODMAP diet affects the gut bacteria and symptoms of people with Irritable Bowel Syndrome (IBS).
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Weizmann Institute of Science Academic / other |
| Locations | 1 site (Rehovot) |
| Status | Recruiting |
| Started | May 11, 2026 |
| Main results expected | January 2028 |
| Study ends | November 2029 |
| Registry record updated | October 15, 2026 |
| Trial ID | NCT05972317 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18-70 who have been diagnosed with IBS.
✕Probably not a fit
Patients with chronic diseases, psychiatric disorders, or those who have recently undergone cancer treatment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the differences in the stool microbiome between treated and untreated patients with Irritable Bowel Syndrome (IBS). It focuses on understanding how dietary factors influence gut microbiome composition and the production of metabolites that may contribute to IBS symptoms. By analyzing the specific small molecules and bacteria involved, the study aims to uncover the mechanisms behind IBS and its flares. Participants will follow a low FODMAP dietary regimen to assess its impact on their microbiome and symptoms.
Why it matters
Potential benefit: If successful, this study could lead to personalized dietary recommendations that improve the management of IBS symptoms.
How similar studies have gone: Other studies have shown promising results in understanding the gut microbiome's role in IBS, suggesting that this approach could yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and Female * Age - 18-70 Exclusion Criteria: * Consumption of antibiotics 2 months prior to enrolment. * Consumption of probiotic supplements 2 weeks prior to enrolment. * Type 1 or type 2 diabetes diagnosis. * Pregnancy, fertility treatments, breastfeeding 3 months prior to the first day of the study. * Chronic disease - to the discretion of the study medical team. * Cancer and recent anticancer treatment. * Immunosuppression. * Psychiatric disorders - to the discretion of the medical team * History of gastrointestinal surgeries - to the discretion of the medical team * Inflammatory bowel diseases or gastrointestinal disorders - to the discretion of the medical team * Unstable doses of medications in the past 2 months * Alcohol or substance abuse.
Where it's running
-
Weizmann institute of science
Rehovot, Israel Recruiting
Study contacts
- Principal investigator: Eran Elinav, Prof — Weizmann Institute of Science
- Study coordinator: Yotam Cohen
- Email: Yotam.cohen@weizmann.ac.il
- Phone: +97289529173
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity
This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.
-
Repeated transcranial magnetic stimulation to treat diarrhea-predominant irritable bowel syndrome
This study will test whether repeated transcranial magnetic stimulation (rTMS) can reduce diarrhea, abdominal pain, and improve quality of life in adults with IBS-D.
-
Brenipatide (LY3537031) for IBS with constipation
This trial will test whether brenipatide (LY3537031), given by a small under-the-skin injection, helps adults with IBS-C have less belly pain and more normal bowel movements compared with a placebo.
-
Brenipatide (LY3537031) treatment for adults with IBS‑D
This will test whether brenipatide (LY3537031) given under the skin helps adults with IBS‑D reduce belly pain and improve stool consistency compared with placebo.
-
Camlipixant for IBS-D and IBS-M: a test in adults
This study tests camlipixant versus placebo in adults with IBS with diarrhea or mixed IBS to see if it helps reduce symptoms and is safe.
-
Defining Objective Markers of Dietary Compliance in IBS
This study tests whether a biomarker in stool or urine can reflect how much certain carbohydrates you eat, helping manage IBS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.